Japan Antidiabetics Market Size & Outlook, 2023-2030

The antidiabetics market in Japan is expected to reach a projected revenue of US$ 4,798.5 million by 2030. A compound annual growth rate of 8.6% is expected of Japan antidiabetics market from 2024 to 2030.
Revenue, 2023 (US$M)
$2,698.7
Forecast, 2030 (US$M)
$4,798.5
CAGR, 2024 - 2030
8.6%
Report Coverage
Japan

Japan antidiabetics market highlights

  • The Japan antidiabetics market generated a revenue of USD 2,698.7 million in 2023 and is expected to reach USD 4,798.5 million by 2030.
  • The Japan market is expected to grow at a CAGR of 8.6% from 2024 to 2030.
  • In terms of segment, glp-1 receptor agonists was the largest revenue generating drug class in 2023.
  • GLP-1 Receptor Agonists is the most lucrative drug class segment registering the fastest growth during the forecast period.

Antidiabetics market data book summary

Market revenue in 2023USD 2,698.7 million
Market revenue in 2030USD 4,798.5 million
Growth rate8.6% (CAGR from 2023 to 2030)
Largest segmentGlp-1 receptor agonists
Fastest growing segmentGLP-1 Receptor Agonists
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationGLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Others Drug Class, Insulin
Key market players worldwideAstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Co Ltd, Eli Lilly and Co, Boehringer Ingelheim, Bristol-Myers Squibb Co, Pfizer Inc, Johnson & Johnson, Merck & Co Inc, Novartis AG ADR

Other key industry trends

  • In terms of revenue, Japan accounted for 3.7% of the global antidiabetics market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, Japan antidiabetics market is projected to lead the regional market in terms of revenue in 2030.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,922.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Antidiabetics Market Companies

Name Profile # Employees HQ Website

Japan antidiabetics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antidiabetics market will help companies and investors design strategic landscapes.


Glp-1 receptor agonists was the largest segment with a revenue share of 35.49% in 2023. Horizon Databook has segmented the Japan antidiabetics market based on glp-1 receptor agonists, dpp- 4 inhibitors, sglt2 inhibitors, others drug class, insulin covering the revenue growth of each sub-segment from 2018 to 2030.


  • Japan Antidiabetics Drug Class Outlook (Revenue, USD Million, 2018-2030)
    • GLP-1 Receptor Agonists
    • DPP- 4 Inhibitors
    • SGLT2 Inhibitors
    • Others Drug Class
    • Insulin
      • Long-acting insulin
      • Premix insulin
      • Fast-acting insulin
      • Human insulin
  • Japan Antidiabetics Diabetes Type Outlook (Revenue, USD Million, 2018-2030)
    • Type 1
    • Type 2
  • Japan Antidiabetics Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Japan Antidiabetics Route of Administration Outlook (Revenue, USD Million, 2018-2030)
    • Oral
    • Subcutaneous
    • Intravenous

Reasons to subscribe to Japan antidiabetics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan antidiabetics market databook

  • Our clientele includes a mix of antidiabetics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan antidiabetics market, including forecasts for subscribers. This country databook contains high-level insights into Japan antidiabetics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan antidiabetics market size, by drug class, 2018-2030 (US$M)

Japan Antidiabetics Market Share, 2023 & 2030 (US$M)

Japan antidiabetics market size, by drug class, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more